Balaz, DavidWikman Jorgensen, Philip ErickGalvañ, Vicente GinerRubio Rivas, Manuelde Miguel Campo, BorjaLópez, Mariam NoureddineLópez Caleya, Juan FranciscoHuelgas, Ricardo GómezPesqueira Fontán, Paula MaríaBailón, Manuel MéndezFernández Garcés, MarFernández Cruz, AnaGarcía García, Gema MaríaRhyman, NicolásCorral Gudino, LuisRodríguez Mancheño, Aquiles LozanoDe La Chica, María NavarroTorregrosa García, AndreaAlcalá, José NicolásDíaz Jiménez, PabloRoyo Trallero, Leticia EstherComas Casanova, PereNúñez Cortés, Jesús MillánCasas Rojo, José-Manuel2023-06-162023-06-162021-10-082077-038310.3390/jcm10194610https://hdl.handle.net/20.500.14352/5055Objectives: Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. Material and methods: A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. Results: CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; p < 0.001), with hypertension (57.0% vs. 47.7%; p < 0.001), obesity (26.4% vs. 19.3%; p < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; p < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7–160) vs. 49.3 (16–109) mg/dL; p < 0.001), ferritin (791 (393–1534) vs. 470 (236–996) µg/dL; p < 0.001), D dimer (750 (430–1400) vs. 617 (345–1180) µg/dL; p < 0.001), and lower Sp02/Fi02 (266 (91.1) vs. 301 (101); p < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; p < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Conclusions: Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%.engAtribución 3.0 Españajournal articlehttps://doi.org/10.3390/jcm10194610https://www.mdpi.com/2077-0383/10/19/4610open access616.9COVID-19CorticosteroidsSpainComorbiditiesMedicinaEnfermedades infecciosas32 Ciencias Médicas3205.05 Enfermedades Infecciosas